BiotechTube

Zurampic® + Control group: xanthine oxidase inhibitor monotherapy

Pre-clinicalWithdrawn
0 watching 0 views this week💤 Quiet
23
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Gout

Conditions

Gout, Hyperuricemia

Trial Timeline

Jan 29, 2021 → Jun 30, 2023

NCT ID
NCT04072471

About Zurampic® + Control group: xanthine oxidase inhibitor monotherapy

Zurampic® + Control group: xanthine oxidase inhibitor monotherapy is a pre-clinical stage product being developed by AstraZeneca for Gout. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT04072471. Target conditions include Gout, Hyperuricemia.

Hype Score Breakdown

Clinical
5
Activity
2
Company
10
Novelty
2
Community
1

Clinical Trials (1)

NCT IDPhaseStatus
NCT04072471Pre-clinicalWithdrawn

Competing Products

20 competing products in Gout

See all competitors
ProductCompanyStageHype Score
febuxostat + AllopurinolAstellas PharmaPhase 3
77
Dotinurad + FebuxostatEisaiPhase 3
77
BaricitinibEli LillyPhase 2
52
HR091506 tablets + placebo of febuxostat tablets + febuxostat tablets + placebo of HR091506 tabletsJiangsu Hengrui MedicinePhase 1
33
SHR4640 tablet + SHR4640 tablet + febuxostat tablet + SHR4640 placebo tabletJiangsu Hengrui MedicinePhase 2
52
repaglinide; midazolam; SHR4640 + repaglinide; midazolam; SHR4640; SHR4640 placebo + repaglinide; midazolam; SHR4640 placeboJiangsu Hengrui MedicinePhase 1
33
SHR4640 + placeboJiangsu Hengrui MedicinePhase 1
33
SHR4640 dose1 + SHR4640 dose2 + Placebo oral tablet + Allopurinol 300 MGJiangsu Hengrui MedicinePhase 3
77
Colchicine + Febuxostat + SHR4640Jiangsu Hengrui MedicinePhase 1
33
SHR4640 + AllopurinolJiangsu Hengrui MedicinePhase 3
77
SHR4640 ；Febuxostat + SHR4640 ; Febuxostat + SHR4640 + SHR4640 + FebuxostatJiangsu Hengrui MedicinePhase 2
52
SHR4640Jiangsu Hengrui MedicinePhase 1
33
HR091506 tablets + placebo of febuxostat tablets + febuxostat tablets + placebo of HR091506 tabletsJiangsu Hengrui MedicinePhase 3
77
HR091506 tablets + placebo of febuxostat tablets + febuxostat tablets + placebo of HR091506 tabletsJiangsu Hengrui MedicinePhase 3
77
SHR4640 + PlaceboJiangsu Hengrui MedicinePhase 1
33
Risk of selected safety eventsAstraZenecaPre-clinical
23
AZD6140 + Placebo to match AZD6140AstraZenecaPhase 1
33
RDEA3170 + Allopurinol + PlaceboAstraZenecaPhase 2
52
RDEA3170 + Febuxostat + BenzbromaroneAstraZenecaPhase 1/2
41
Canakinumab pre-filled syringe + Canakinumab lyophilized powder + Triamcinolone Acetonide + PlaceboNovartisPhase 3
77

Other Products from AstraZeneca

QuetiapineApproved
85
Dapagliflozin 5 mg + Placebo tabletApproved
85
QuetiapineApproved
85
Ticagrelor + ClopidogrelApproved
85
DurvalumabApproved
85